FibroBiologics (FBLG) Competitors $1.12 +0.08 (+7.69%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBLG vs. DSGN, ENGN, PLX, OCGN, AMRN, NVCT, MDWD, RZLT, CRDF, and IVAShould you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Design Therapeutics (DSGN), enGene (ENGN), Protalix BioTherapeutics (PLX), Ocugen (OCGN), Amarin (AMRN), Nuvectis Pharma (NVCT), MediWound (MDWD), Rezolute (RZLT), Cardiff Oncology (CRDF), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. FibroBiologics vs. Design Therapeutics enGene Protalix BioTherapeutics Ocugen Amarin Nuvectis Pharma MediWound Rezolute Cardiff Oncology Inventiva FibroBiologics (NASDAQ:FBLG) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Does the MarketBeat Community believe in FBLG or DSGN? FibroBiologics received 3 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave FibroBiologics an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformFibroBiologicsOutperform Votes13100.00% Underperform VotesNo VotesDesign TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Do insiders & institutionals have more ownership in FBLG or DSGN? 56.6% of Design Therapeutics shares are held by institutional investors. 20.8% of FibroBiologics shares are held by insiders. Comparatively, 31.2% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, FBLG or DSGN? Design Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroBiologicsN/AN/A-$16.49M-$0.34-3.29Design TherapeuticsN/AN/A-$66.86M-$0.88-5.52 Is FBLG or DSGN more profitable? FibroBiologics' return on equity of 0.00% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets FibroBiologicsN/A N/A -225.34% Design Therapeutics N/A -18.01%-17.38% Which has more risk and volatility, FBLG or DSGN? FibroBiologics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Do analysts recommend FBLG or DSGN? FibroBiologics presently has a consensus price target of $13.00, indicating a potential upside of 1,060.71%. Design Therapeutics has a consensus price target of $8.00, indicating a potential upside of 64.61%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts clearly believe FibroBiologics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor FBLG or DSGN? In the previous week, FibroBiologics had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.21 beat FibroBiologics' score of 0.72 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment FibroBiologics Positive Design Therapeutics Positive SummaryFibroBiologics beats Design Therapeutics on 11 of the 16 factors compared between the two stocks. Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBLG vs. The Competition Export to ExcelMetricFibroBiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.79M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-3.297.4422.4818.48Price / SalesN/A242.70395.10103.59Price / CashN/A65.8538.1834.62Price / Book28.006.516.774.25Net Income-$16.49M$143.21M$3.22B$248.23M7 Day Performance-13.18%1.98%1.50%0.89%1 Month Performance30.23%6.89%4.01%3.53%1 Year Performance-85.88%-2.52%16.16%5.08% FibroBiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBLGFibroBiologics2.6698 of 5 stars$1.12+7.7%$13.00+1,060.7%-88.1%$39.79MN/A-3.2910Short Interest ↓Gap UpDSGNDesign Therapeutics1.8549 of 5 stars$3.59+2.6%$8.00+122.8%+38.1%$203.78MN/A-4.2240Upcoming EarningsPositive NewsENGNenGene3.3862 of 5 stars$3.99-0.3%$24.13+504.6%-74.0%$203.40MN/A-6.8831Analyst ForecastShort Interest ↑PLXProtalix BioTherapeutics2.6825 of 5 stars$2.55-2.3%$15.00+488.2%+169.3%$198.98M$53.40M-19.62200Positive NewsOCGNOcugen0.9152 of 5 stars$0.68-0.3%$6.33+835.4%-43.4%$197.72M$4.06M-3.7680AMRNAmarin0.6498 of 5 stars$9.55+4.8%$7.00-26.7%-41.6%$196.10M$228.61M-106.11360Upcoming EarningsAnalyst RevisionGap DownNVCTNuvectis Pharma2.615 of 5 stars$8.34-5.9%$15.67+87.8%+63.8%$195.09MN/A-7.198Upcoming EarningsAnalyst ForecastNews CoverageMDWDMediWound1.4404 of 5 stars$17.65+3.2%$31.33+77.5%-4.9%$190.76M$20.22M-6.0980RZLTRezolute2.6932 of 5 stars$3.14+14.2%$26.43+741.7%+40.3%$190.08MN/A-2.5740Analyst ForecastShort Interest ↑Positive NewsHigh Trading VolumeCRDFCardiff Oncology1.4317 of 5 stars$2.82-1.1%$11.67+313.7%-37.2%$187.60M$683,000.00-3.0020News CoverageIVAInventiva1.9363 of 5 stars$3.56+6.0%$10.40+192.1%+17.1%$186.82M$9.20M0.00100 Related Companies and Tools Related Companies DSGN Competitors ENGN Competitors PLX Competitors OCGN Competitors AMRN Competitors NVCT Competitors MDWD Competitors RZLT Competitors CRDF Competitors IVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBLG) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FBLG Stock Free FBLG Stock Alerts